Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Azd5492 – Application in Therapy and Current Clinical Research
Azd5492 – Aplicación en terapia e investigaciones clínicas actuales
Study on the Safety and Effectiveness of AZD5492 Alone or with Other ...
TITANium: An open-label, global multicenter phase 1/2 study of AZD5492 ...
AZD5492: A Novel T Cell Engager for NHL | PDF | T Cell | Interleukin 10
阿斯利康「CD20×TCR×CD8三抗」在华获批临床 研究开发 | 华源医药网
阿斯利康1类新药AZD5492在中国获批临床，有望提高B细胞淋巴瘤疗效_摩熵医药
TITANium: A MULTICENTER PHASE 1/2 STUDY OF AZD5492, A FIRST‐IN‐CLASS ...
阿斯利康1类新药AZD5492在中国获批临床，有望提高B细胞淋巴瘤疗效_摩熵医药(原药融云)
tilatamig samrotecan (AZD9592) / AstraZeneca
阿斯利康三特异性抗体癌症新药在中国申报临床_细胞_https_研究
Paper: Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell ...
Effect of AZD8542 in an orthotopic model of pancreatic cancer with ...
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and ...
AZD-5492(AZD-5492) - 药物靶点：CD20 x CD3 x CD8 x TCRs_在研适应症：B细胞恶性肿瘤，慢性淋巴细胞 ...
AZD-5492(AZD-5492) - 药物靶点：CD20 x CD8 x TCR_在研适应症：B细胞恶性肿瘤，慢性淋巴细胞白血病，特发性 ...
Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager ...
三抗新药AZD5492治疗系统性红斑狼疮或特发性炎症性肌病_细胞_mg_研究
B-cell depletion. Freshly isolated PBMCs were incubated for two days ...
Novel Tri-Specific T-Cell Engager May Reduce Toxicity, Improve Safety ...
Schematic diagram showing the molecular mechanism by which the SR-4835 ...
TCE类药物，迎来了高光时刻医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康「CD20×TCR×CD8三抗」在华获批临床_药智新闻
Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune ...
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion ...
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条
T-Cell Engagers—The Structure and Functional Principle and Application ...
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric ...
